How Testosterone Enanthate Affects Haematocrit

Testosterone stimulates erythropoiesis (red blood cell production) through two complementary pathways:

1. EPO upregulation: Testosterone increases renal erythropoietin (EPO) production, signalling the bone marrow to produce more red blood cells.
2. Hepcidin suppression: Androgens suppress hepcidin, the master iron-regulatory hormone, which increases iron availability for haemoglobin synthesis.
3. Direct marrow stimulation: Androgens act directly on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation.

The net effect is a dose-dependent rise in both haemoglobin and haematocrit. This is the most common adverse finding on TRT blood work, affecting roughly 20% of men on standard replacement doses and a higher proportion of those using supraphysiological doses.

Replacement doses (100-200 mg/week):

• Haematocrit typically rises 2-5 percentage points within the first 3-6 months
• Most men stabilise between 48-52%
• Approximately 10-20% exceed 54%, the clinical threshold for intervention

Supraphysiological doses (300-600+ mg/week):

• Haematocrit can rise 5-10+ percentage points
• Values of 54-58% are common, with some users exceeding 60%
• The increase is more rapid, often noticeable within 6-8 weeks

Timing: The rise begins within 2-4 weeks but typically peaks at 3-6 months. Once elevated, haematocrit tends to remain high for as long as testosterone is administered.

Baseline: Always obtain a CBC before starting testosterone. Men with haematocrit above 50% at baseline are at higher risk.

First year: Check every 3 months (at trough, before your next injection). This is the period of greatest change.

Stable patients: Every 6 months once haematocrit has been stable for two consecutive checks.

High-risk triggers for extra monitoring:

• Dose increase
• Switch from frequent to infrequent injections (higher peaks)
• Starting a blast or adding a second androgen
• Altitude change (moving to a higher elevation)
• Symptoms: headaches, visual disturbance, chest tightness, facial flushing

If haematocrit is 50-54%:

• Increase injection frequency (e.g., from weekly to every 3.5 days) to lower peak testosterone levels
• Ensure adequate hydration (dehydration falsely elevates haematocrit)
• Consider naringin (grapefruit extract) 500-1000 mg/day for mild EPO modulation
• Recheck in 4-6 weeks

If haematocrit exceeds 54%:

• Reduce testosterone dose by 10-20%
• Switch to more frequent, smaller injections
• Therapeutic phlebotomy (donate blood or medical venesection) removes 1 unit (450-500 mL), typically lowering haematocrit by 3-4 points
• Recheck 2-4 weeks after phlebotomy

If haematocrit exceeds 58%:

• Urgent medical review; this level carries meaningful thrombotic risk
• Consider pausing testosterone until haematocrit drops below 52%
• Serial phlebotomy may be needed

Long-term strategies:

• Regular blood donation (if eligible) is an effective ongoing management tool
• Low-dose aspirin (75-100 mg/day) is sometimes used for additional antiplatelet protection, though evidence is debated